š° Brainstorm Cell News
Page 32 - Brainstorm Cell News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Brainstorm Cell. Real-time updates on events, politics, business and more.
May 16, 2022
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
May 4, 2022
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the...
May 3, 2022
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces...
April 25, 2022
Press release content from PR.com. The AP news staff was not involved in its creation.
April 24, 2022
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Profitability This table compares Brainstorm Cell Therapeutics and […]
April 20, 2022
Equities analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to announce earnings of ($0.13) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which would […]
April 6, 2022
Brokerages expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to post ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.13). Brainstorm Cell Therapeutics posted earnings per share of ($0.19) during […]
February 15, 2022
/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
December 14, 2021
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn'sĀ® Phase 3 Study for ALS in Muscle and Nerve - read this article along with other careers information, tips and advice on BioSpace
December 13, 2021
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...